RU2124501C1 - Производные салициловой кислоты, их алкиловые эфиры, содержащие от 1 до 6 атомов углерода в эфирной группе, соли и сольваты - Google Patents

Производные салициловой кислоты, их алкиловые эфиры, содержащие от 1 до 6 атомов углерода в эфирной группе, соли и сольваты Download PDF

Info

Publication number
RU2124501C1
RU2124501C1 RU94028109A RU94028109A RU2124501C1 RU 2124501 C1 RU2124501 C1 RU 2124501C1 RU 94028109 A RU94028109 A RU 94028109A RU 94028109 A RU94028109 A RU 94028109A RU 2124501 C1 RU2124501 C1 RU 2124501C1
Authority
RU
Russia
Prior art keywords
hydroxy
methyl
ethynyl
spin system
phenyl
Prior art date
Application number
RU94028109A
Other languages
English (en)
Russian (ru)
Other versions
RU94028109A (ru
Inventor
Хуберт Агбак Карл
Ахргрен Лейф
Берглинд Томас
Харальдссон Мартин
Ольссон Ларс-Инге
Смедегорд Геран
Original Assignee
Фармациа АБ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармациа АБ filed Critical Фармациа АБ
Publication of RU94028109A publication Critical patent/RU94028109A/ru
Application granted granted Critical
Publication of RU2124501C1 publication Critical patent/RU2124501C1/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
RU94028109A 1991-11-18 1992-11-04 Производные салициловой кислоты, их алкиловые эфиры, содержащие от 1 до 6 атомов углерода в эфирной группе, соли и сольваты RU2124501C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9103397A SE9103397D0 (sv) 1991-11-18 1991-11-18 Nya substituerade salicylsyror
SE9103397-7 1991-11-18

Publications (2)

Publication Number Publication Date
RU94028109A RU94028109A (ru) 1996-01-10
RU2124501C1 true RU2124501C1 (ru) 1999-01-10

Family

ID=20384352

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94028109A RU2124501C1 (ru) 1991-11-18 1992-11-04 Производные салициловой кислоты, их алкиловые эфиры, содержащие от 1 до 6 атомов углерода в эфирной группе, соли и сольваты

Country Status (29)

Country Link
US (3) US5302718A (enExample)
EP (1) EP0613468B1 (enExample)
JP (1) JP3259915B2 (enExample)
KR (1) KR100253748B1 (enExample)
AT (1) ATE194597T1 (enExample)
AU (1) AU668528B2 (enExample)
CA (1) CA2123697C (enExample)
DE (1) DE69231252T2 (enExample)
DK (1) DK0613468T3 (enExample)
EE (1) EE03026B1 (enExample)
ES (1) ES2149780T3 (enExample)
FI (1) FI106857B (enExample)
GR (1) GR3034585T3 (enExample)
HU (2) HU221476B (enExample)
IL (1) IL103665A (enExample)
LT (1) LT3182B (enExample)
LV (1) LV10246B (enExample)
MX (1) MX9206647A (enExample)
MY (1) MY130169A (enExample)
NO (1) NO300805B1 (enExample)
NZ (1) NZ244998A (enExample)
PT (1) PT101068B (enExample)
RU (1) RU2124501C1 (enExample)
SE (1) SE9103397D0 (enExample)
SK (1) SK282080B6 (enExample)
TW (1) TW304944B (enExample)
UA (1) UA42869C2 (enExample)
WO (1) WO1993010094A1 (enExample)
ZA (1) ZA928864B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2481329C2 (ru) * 2008-06-23 2013-05-10 Астеллас Фарма Инк. Сульфонамидные соединения или их соли

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
GB9310095D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Therapeutic compounds
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5405842A (en) * 1994-01-28 1995-04-11 Silverman; Bernard A. Treatment of steroid dependent asthmatics
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
EP0788353A1 (en) 1995-09-18 1997-08-13 Ligand Pharmaceuticals, Inc. Ppar gamma antagonists for treating obesity
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
AU717230B2 (en) 1996-02-20 2000-03-23 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
JP3814742B2 (ja) * 1996-10-18 2006-08-30 イハラケミカル工業株式会社 ４−フルオロサリチル酸類
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9804648D0 (en) 1998-03-06 1998-04-29 Zeneca Ltd Chemical compounds
GB9805520D0 (en) 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
GB9811427D0 (en) 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
CA2334545A1 (en) 1998-06-12 1999-12-16 Ligand Pharmaceuticals Incorporated Treatment of anti-estrogen resistant breast cancer using rxr modulators
CA2367916A1 (en) 1999-03-19 2000-09-28 Ambarish Singh Methods for the preparation of biphenyl isoxazole sulfonamides
AU6715200A (en) 1999-09-04 2001-04-10 Astrazeneca Ab Amides as inhibitors for pyruvate dehydrogenase
CZ2002773A3 (cs) 1999-09-04 2002-06-12 Astrazeneca Ab Substituované deriváty N-fenyl-2-hydroxy-2-methyl-3,3,3-trifluorpropanamidu, které zvyąují aktivitu pyruvátdehydrogenázy
DE60031699T2 (de) 1999-09-04 2007-08-30 Astrazeneca Ab Hydroxyacetamidobenzolsulfonamidderivate
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
EP1278521B1 (en) * 2000-04-28 2005-11-30 The University of British Columbia N-heterocyclic substituted salicylates for the treatment of cancer
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
KR100360342B1 (ko) * 2002-04-19 2002-11-13 박계정 밸런스 머신의 언밸런스 수정위치 및 수정량의 자동 보상방법
EP1661889A4 (en) * 2003-09-05 2009-08-05 Ono Pharmaceutical Co ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
BRPI0417687A (pt) * 2003-12-19 2007-04-03 Pfizer derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade
BRPI0512915A (pt) * 2004-06-29 2008-04-15 Warner Lambert Co terapias de combinação utilizando inibidores benzamida do receptor p2x7
GB2421947A (en) * 2005-01-07 2006-07-12 Univ Southampton Sulphonamide compounds for use as inhibitors of NF-kB
MX2008010668A (es) * 2006-02-21 2008-10-01 Amgen Inc Derivados de cinolina como inhibidores de fosfodiesterasa 10.
EP2677865A4 (en) * 2011-02-23 2015-04-22 Icahn School Med Mount Sinai BROMODOMAIN INHIBITORS AS MODULATORS OF GENE EXPRESSION
MA42145B1 (fr) 2015-05-20 2020-05-29 Amgen Inc Triazoles agonistes du récepteur apj
WO2017123826A1 (en) 2016-01-14 2017-07-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
EP3452466B1 (en) 2016-05-03 2020-08-12 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
EP3541802B1 (en) 2016-11-16 2025-01-01 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
EP3788037A1 (en) 2018-05-01 2021-03-10 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
CN111056978B (zh) * 2019-12-13 2021-01-19 西安交通大学 一种磺酰胺类化合物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2396145A (en) * 1940-12-14 1946-03-05 Pharmscia Ab Heterocyclic sulphonamido azo compounds
US3915951A (en) * 1971-11-26 1975-10-28 Pharmacia Ab 4(3-Carboxy-4-hydroxyphenylazo)-benzenlsulphonamide pyridine compounds having immunosuppressive effects
EP0148725A1 (en) * 1984-01-06 1985-07-17 Shionogi & Co., Ltd. Sulfonamido-benzamide derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663334A (en) * 1985-12-11 1987-05-05 Mcneilab, Inc. Heteroaromatic acetylenes useful as antihypertensive agents
US4897397A (en) * 1988-12-16 1990-01-30 Schering Corporation Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2396145A (en) * 1940-12-14 1946-03-05 Pharmscia Ab Heterocyclic sulphonamido azo compounds
US3915951A (en) * 1971-11-26 1975-10-28 Pharmacia Ab 4(3-Carboxy-4-hydroxyphenylazo)-benzenlsulphonamide pyridine compounds having immunosuppressive effects
EP0148725A1 (en) * 1984-01-06 1985-07-17 Shionogi & Co., Ltd. Sulfonamido-benzamide derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2481329C2 (ru) * 2008-06-23 2013-05-10 Астеллас Фарма Инк. Сульфонамидные соединения или их соли

Also Published As

Publication number Publication date
UA42869C2 (uk) 2001-11-15
SK54794A3 (en) 1995-02-08
CA2123697C (en) 2003-12-09
US5556855A (en) 1996-09-17
GR3034585T3 (en) 2001-01-31
HU221476B (en) 2002-10-28
TW304944B (enExample) 1997-05-11
SE9103397D0 (sv) 1991-11-18
LV10246A (lv) 1994-10-20
AU2958992A (en) 1993-06-15
HU9401391D0 (en) 1994-08-29
NZ244998A (en) 1995-09-26
EP0613468B1 (en) 2000-07-12
KR100253748B1 (ko) 2000-05-01
HU211163A9 (en) 1995-10-30
IL103665A (en) 1997-08-14
SK282080B6 (sk) 2001-10-08
DE69231252D1 (de) 2000-08-17
EE03026B1 (et) 1997-08-15
DK0613468T3 (da) 2000-10-23
NO941799D0 (no) 1994-05-13
FI942289L (fi) 1994-05-17
EP0613468A1 (en) 1994-09-07
JP3259915B2 (ja) 2002-02-25
FI106857B (fi) 2001-04-30
JPH07501330A (ja) 1995-02-09
ES2149780T3 (es) 2000-11-16
PT101068B (pt) 1999-08-31
HUT69723A (en) 1995-09-28
MY130169A (en) 2007-06-29
MX9206647A (es) 1993-05-01
PT101068A (pt) 1994-02-28
ZA928864B (en) 1993-05-13
WO1993010094A1 (en) 1993-05-27
NO300805B1 (no) 1997-07-28
AU668528B2 (en) 1996-05-09
IL103665A0 (en) 1993-04-04
CA2123697A1 (en) 1993-05-27
NO941799L (enExample) 1994-06-22
ATE194597T1 (de) 2000-07-15
LV10246B (en) 1995-04-20
US5403930A (en) 1995-04-04
LTIP229A (en) 1994-09-25
FI942289A0 (fi) 1994-05-17
LT3182B (en) 1995-03-27
DE69231252T2 (de) 2001-03-01
US5302718A (en) 1994-04-12

Similar Documents

Publication Publication Date Title
EP0613468B1 (en) Substituted salicylic acids for the treatment of autoimmune diseases
RU2145595C1 (ru) Нитроксисоединения и фармацевтическая композиция на их основе, имеющие противовоспалительную, анальгетическую и антитромбоцитарную активности
EP0288973A2 (en) Benzothiazolinone derivatives, their production and pharmaceutical composition
HU179492B (en) Process for producing 1,2,4-thiadiasole derivatives
JPH037263A (ja) アミノベンゼンスルホン酸誘導体
JPH03505335A (ja) ベンゾサイクリックまたはベンゾヘテロサイクリック酸由来の新規スルホンアミド、その製造法およびその医薬用途
US6051588A (en) Nitroso esters of β-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
JPH0374375A (ja) 抗炎症剤としてのフエナメート１，３，４‐チアジアゾール類および１，３，４‐オキサジアゾール類
EP0430459A1 (en) Tetrahydronaphthalene derivatives and preparation thereof
US5519043A (en) Fluorenyl derivatives
KR880002706B1 (ko) 설포닐 우레아의 제조방법
CN113999148B (zh) 一种n-(4-(取代磺酰基氨基)苯基)磺酰胺类化合物及其应用
EP0197386B1 (en) 2-(substituted sulfamyl) derivatives of 6-nitrobenzoic acid, process for their preparation and pharmaceutical compositions containing them
PT91576B (pt) Processo para a preparacao de de sulfonamidas contendo o radical tetrazolilo e de composicoes farmaceuticas que as contem
EP0330380B1 (en) Novel indanoxyacetic acid derivatives and processes for preparing the same
JPS61268680A (ja) 新規なイソオキサゾール誘導体
BRPI0619282B1 (pt) Sal, e composição farmacêutica
IL42558A (en) History of N - Transformed - 'N -} 4 -] 2 -) 2 - Aminobenzamido (ethyl [benzene {and N] 2 - Aminobenzamido (India] Sulfonylurea and process for their preparation
JPS61267542A (ja) アミノベンズアミド化合物
EP0685470A2 (en) Benzene derivatives and pharmaceutical composition
CZ287285B6 (cs) Nové substituované salicylové kyseliny
US3991188A (en) 3-Alkyl-4-sulfamoyl-aniline therapeutic compositions
JPS62240657A (ja) Ｎα−アリ−ルスルホニルアミノアシル−ｐ−アミジノフエニルアラニンアミド誘導体、その製造方法、該誘導体を含む医薬及び該誘導体の合成のための中間体
JPS63183557A (ja) 放射線療法の補助剤として有用な２−（置換スルフアミル）−６−ニトロ安息香酸類誘導体

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20061105